Clinical Trial Update: Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) [Phase 2]

View source ↗

Summary

Phase 2 study of the BTK inhibitor BGB-3111 (zanubrutinib) in Chinese patients with relapsed/refractory Waldenström's macroglobulinemia has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• BGB-3111 (zanubrutinib) (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Waldenström's Macroglobulinemia (WM) | Phase 2 | Status: COMPLETED | Results posted: 2022-03-08